It is worth noting that thyroid cancer patients with mutations in PIK3CA or AKT1 almost always also have BRAF mutations (24), indicating an interaction between the RAS/BRAF/MAPK pathway and the PI3K/AKT pathway in driving thyroid cancer development. Here, AKT1 is linked to thyroid gland carcinoma.